Enesi Pharma Ltd., of Oxford, U.K., said it inked an agreement with scientists at the Oxford Vaccine Group (OVG) at the University of Oxford to create and test a solid dose vaccine against plague. The collaboration will leverage Enesi's Implavax needle-free technology and a vaccine based on a ChAdOx adenovirus vector that was developed by OVG against the bacteria-causing plague Yersinia pestis.